R&D | Cutting-edge science and innovative research

News

US is planning $500m project on 'universal vaccines;' WSJ

The US will spend $500m to develop universal vaccines against multiple virus variants, while planned changes to testing rules are raising concerns.

News

Senator Susan Collins, chair of the Appropriations Committee

Senior Republican hits out at Trump's research funding cuts

The Republican chair of the Appropriations Committee has slammed the Trump administration for actions that are putting US biomedical research at risk.

R&D

female researchers looking at results on a computer screen

Driving innovation and improving patient outcomes through in...

Achieving diversity and inclusion in medical research is essential for advancing healthcare, discovering novel drug therapies, and achieving overall health equity.

News

Shreeram Aradhye, Novartis' chief medical officer

Novartis grabs kidney drug developer Regulus in $1.7bn deal

Novartis has grown in renal diseases once again with a $1.7bn deal to buy Regulus and its autosomal dominant polycystic kidney disease (ADPKD) drug.

News

AstraZeneca's Discovery Centre in Cambridge

AZ backs up threat of manufacturing shift from Europe

AstraZeneca has said it is considering a shift in the production of some medicines from Europe to the US in order to sidestep potential tariffs.

News

Granite Bio makes $100m debut, and other bio financings

Our round-up of recent biotech financings includes rounds for Granite Bio, Biolinq, Etiome, Grove Biopharma, and Synthetic Design Lab.

R&D

Partner Content

4th In Vivo Cell Engineering & Gene Editing Summit

This forum brings together the brightest minds from biopharma, academia, and regulatory leadership to explore the full translational journey

News

Hands uniting in the centre of a circle of children

Irish study promises to revolutionise childhood cancer care

A five-year genomics study that aims to transform the care of children with cancer and improve treatment success has launched in Ireland.

Debates & Insights

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Webinars

Sponsored

Synthetic control arms in clinical trials: Making it happen

Across the industry, pharma companies are turning to AI and real-world data to address many of the challenges of running clinical trials.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/live.png

Webinars

Sponsored

How synthetic control arms are changing clinical trials

Clinical trials are involved, expensive, and have been done largely the same way for decades but with today’s technology all that can change.

News

US is planning $500m project on 'universal vaccines;' WSJ

The US will spend $500m to develop universal vaccines against multiple virus variants, while planned changes to testing rules are raising concerns.

News

Senior Republican hits out at Trump's research funding cuts

The Republican chair of the Appropriations Committee has slammed the Trump administration for actions that are putting US biomedical research at risk.

Press Releases

Views & Analysis

Touring Chiesi's vision for the future at the new Biotech Ce...

Following an invite to fly into Parma, Italy to witness first-hand the press launch of the considerable structure – black-painted and as yet under construction, gigantic cranes and all – th

News

Vir awarded $1 billion multi-year BARDA influenza contract

The US Government’s Biomedical Advanced Research and Development Authority (BARDA) has made an

Views & Analysis

R&D

Driving innovation and improving patient outcomes through in...

Achieving diversity and inclusion in medical research is essential for advancing healthcare, discovering novel drug therapies, and achieving overall health equity.

R&D

Shifting paradigms of clinical trial design accelerate CNS R...

Meeting the demand for clinically relevant neurodegenerative treatments requires a paradigm shift in how central nervous system (CNS) clinical trials have been designed and executed.

R&D

pharmaphorum podcast Episode 174a - Tomasz Kostrzewski, CN Bio

Driving the drug discovery pipeline: The value of organ-on-a...

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Tomasz Kostrzewski, CSO at CN Bio, about single organ-on-a-chip technology.

Deep Dive

R&D

R&D Contraceptive pills condoms and intrauterine device

Research and Development

R&D

Deep Dive: Research and Development 2025

Every breakthrough in medicine, every new treatment that changes lives, starts with research.

R&D

Breaking through financial barriers to clinical trials: How ...

R&D

Sponsored

Exploring the future: Opportunities and challenges in cell a...

Rare disease treatment poses distinct challenges for physicians, patients, caregivers, and pharma companies.

R&D

Sponsored

Beyond clinical: Boosting recruitment and retention with SDO...

The success of clinical trials hinges on a complex array of factors, many of which extend beyond traditional clinical care.

R&D

evolution of clinical research in the UK

Sponsored

The evolution of clinical research: Embracing new delivery m...

The UK is welcoming a new era of clinical trial delivery, evolving beyond the traditional site-centric approach to also embrace remote, decentralised, virtual, and hybrid trials and enablin

Podcasts

R&D

Driving the drug discovery pipeline: The value of organ-on-a...

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Tomasz Kostrzewski, CSO at CN Bio, about single organ-on-a-chip technology.

R&D

pharmaphorum podcast Episode 173a - Sonia A. Veluchamy, Celegence

Intelligent regulatory compliance and improved patient outco...

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Sonia A. Veluchamy, CEO and co-founder of Celegence.

R&D

pharmaphorum podcast Episode 171a - Dean Alms

Safeguarding the pharmaceutical supply chain

Video

R&D

Supercharging clinical development with RWE – with Recursion...

Greater availability of real-world data and real-world evidence is rapidly changing the landscape of drug development.

R&D

Jennifer Schneider’s insights on immunotherapy at JP Morgan ...

Jonah Comstock caught up with Jennifer Schneider, CEO of Centauri Therapeutics, in San Francisco in January during the JP Morgan Healthcare Conference

R&D